Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
暂无分享,去创建一个
[1] T. Sato,et al. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. , 2001, Arthritis and rheumatism.
[2] M. Feldmann,et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. , 1997, British journal of rheumatology.
[3] J. Wells,et al. Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.
[4] V. Goldberg,et al. Green Tea Polyphenol Epigallocatechin-3-gallate (EGCG) Differentially Inhibits Interleukin-1β-Induced Expression of Matrix Metalloproteinase-1 and -13 in Human Chondrocytes , 2004, Journal of Pharmacology and Experimental Therapeutics.
[5] R. Wardale,et al. Up-regulation of matrix metalloproteinase expression and activation following cyclical compressive loading of articular cartilage in vitro. , 2001, Archives of biochemistry and biophysics.
[6] R. Clark,et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor , 1995, The Journal of experimental medicine.
[7] D. Dinakarpandian,et al. Collagenase unwinds triple‐helical collagen prior to peptide bond hydrolysis , 2004, The EMBO journal.
[8] J. Sandy,et al. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. , 1991, The Journal of biological chemistry.
[9] L. Sharma,et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. , 2005, Arthritis and rheumatism.
[10] A. Grodzinsky,et al. Mechanical injury of cartilage explants causes specific time-dependent changes in chondrocyte gene expression. , 2005, Arthritis and rheumatism.
[11] P. Delmas,et al. Biological markers in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.
[12] T. Aigner,et al. Mechanisms of Disease: role of chondrocytes in the pathogenesis of osteoarthritis—structure, chaos and senescence , 2007, Nature Clinical Practice Rheumatology.
[13] Gillian Murphy,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.
[14] J. Delaissé,et al. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. , 2004, Bone.
[15] J. Ward,et al. MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.
[16] T. Cawston,et al. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. , 2005, Current drug targets. Inflammation and allergy.
[17] K. Brew,et al. Reactive Site Mutations in Tissue Inhibitor of Metalloproteinase-3 Disrupt Inhibition of Matrix Metalloproteinases but Not Tumor Necrosis Factor-α-converting Enzyme* , 2005, Journal of Biological Chemistry.
[18] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[19] R. Maki,et al. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. , 2002, Journal of immunology.
[20] D. Woolley,et al. Purification of rheumatoid synovial collagenase and its action on soluble and insoluble collagen. , 1975, European journal of biochemistry.
[21] C. Lapière,et al. Collagenolytic activity in amphibian tissues: a tissue culture assay. , 1962, Proceedings of the National Academy of Sciences of the United States of America.
[22] William C. Parks,et al. Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.
[23] D. Woolley,et al. Collagenase at sites of cartilage erosion in the rheumatoid joint. , 1977, Arthritis and rheumatism.
[24] Shigeyoshi Itohara,et al. The Role of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Antibody-Induced Arthritis , 2002, The Journal of Immunology.
[25] Bernard Pirard,et al. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. , 2007, Drug discovery today.
[26] D. Zukor,et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. , 2005, Arthritis and rheumatism.
[27] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[28] G. Homandberg. Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. , 1999, Frontiers in bioscience : a journal and virtual library.
[29] Y. Okada,et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.
[30] J. Enghild,et al. Altered Proteolytic Activities of ADAMTS-4 Expressed by C-terminal Processing* , 2004, Journal of Biological Chemistry.
[31] J. Calvete,et al. Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor , 1998, The EMBO journal.
[32] T. Brodie,et al. Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. , 2005, Arthritis and rheumatism.
[33] J. Pelletier,et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. , 1989, The Journal of clinical investigation.
[34] T. Miyata,et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. , 2003, Blood.
[35] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[36] R. D. Dyer,et al. Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects* , 2007, Journal of Biological Chemistry.
[37] M. Sporn,et al. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. , 2001, Arthritis and rheumatism.
[38] J. Weidner,et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. , 1997, The Journal of clinical investigation.
[39] J. Wallace,et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.
[40] K. Iwata,et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[41] Gillian Murphy,et al. Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.
[42] J. Enghild,et al. Proteolytic Activities of Human ADAMTS-5 , 2007, Journal of Biological Chemistry.
[43] S. Kumar,et al. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. , 2006, Osteoarthritis and cartilage.
[44] R. Huber,et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.
[45] D. Zukor,et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. , 2002, Arthritis & Rheumatism.
[46] R. Mason,et al. Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. , 2003, Arthritis and rheumatism.
[47] R. Maki,et al. Expression and Regulation of Aggrecanase in Arthritis: The Role of TGF-β1 , 2002, The Journal of Immunology.
[48] B. Bresnihan,et al. Synovial tissue inflammation in early and late osteoarthritis , 2005, Annals of the rheumatic diseases.
[49] Alexander Fraser,et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. , 2003, Arthritis and rheumatism.
[50] J. Pelletier,et al. Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. , 2003, Arthritis and rheumatism.
[51] R. Wynn,et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.
[52] A. Fourie,et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.
[53] D. Edwards,et al. The ADAMTS metalloproteinases. , 2005, The Biochemical journal.
[54] J. White. ADAMs: modulators of cell-cell and cell-matrix interactions. , 2003, Current opinion in cell biology.
[55] A. Parker,et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.